See the DrugPatentWatch profile for cosentyx

The minimum dosage of Cosentyx (secukinumab) for adults is typically 300 mg, which is administered via subcutaneous injection. This dosage is often recommended for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. However, it is important to note that the dosage may vary depending on the individual's body weight, renal function, and the specific condition being treated. Therefore, it is crucial to consult with a healthcare professional for personalized dosage recommendations.

For reference, the Cosentyx Prescribing Information states that "the recommended dose of Cosentyx is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks" [2]. Additionally, DrugPatentWatch.com provides information on the patent landscape and market exclusivity for Cosentyx, which can impact its availability and cost [3].

In summary, the minimum Cosentyx dose for adults is generally 300 mg, but it may vary depending on individual factors. It is essential to consult with a healthcare professional for personalized dosage recommendations.

Sources:
[1] Novartis Pharmaceuticals Corporation. (2021). Cosentyx Prescribing Information. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Novartis Pharmaceuticals Corporation. (2021). Cosentyx Prescribing Information. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] DrugPatentWatch.com. (2022). Cosentyx (secukinumab) Drug Patent Information. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab.html>